CRANFORD, N.J., April 4,
2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
("Citius" or the "Company") (Nasdaq: CTXR), a late-stage
biopharmaceutical company dedicated to the development and
commercialization of first-in-class critical care products, today
announced that Chairman and CEO Leonard
Mazur will present at the 14th Annual LD Micro Invitational
investor conference being held April 8-9,
2024, in New York City.
Conference Details:
Presentation:
|
3:30pm ET on April 9,
2024
|
Format:
|
In-person and
virtual
|
Location:
|
Sofitel New York, New
York City
|
Conference
attendance:
|
Register
on the conference website
|
Livestream:
|
Register
here
|
1x1
meetings:
|
Upon request by
registered investors
|
About Citius Pharmaceuticals, Inc.
Citius Pharma is a late-stage biopharmaceutical company
dedicated to the development and commercialization of
first-in-class critical care products. The Company's diversified
pipeline includes two late-stage product candidates. At the end of
2023, Citius completed enrollment in a Phase 3 Pivotal superiority
trial of Mino-Lok®, an antibiotic lock solution to salvage
catheters in patients with catheter-related bloodstream infections.
A Biologics License Application for LYMPHIR™, a novel IL-2R
immunotherapy for an initial indication in the treatment of
cutaneous T-cell lymphoma, is currently under review by the FDA
with August 13, 2024 assigned as the
PDUFA target action date. Citius previously announced plans to form
Citius Oncology, a standalone publicly traded company with LYMPHIR
as its primary asset. LYMPHIR received orphan drug designation by
the FDA for the treatment of CTCL and PTCL. In addition, Citius
completed enrollment in its Phase 2b
trial of CITI-002 (Halo-Lido), a topical formulation for the relief
of hemorrhoids. For more information, please
visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-ld-micro-invitational-xiv-investor-conference-302108125.html
SOURCE Citius Pharmaceuticals, Inc.